Last reviewed · How we verify
Desferal
At a glance
| Generic name | Desferal |
|---|---|
| Also known as | Deferoxamine, deferoxamine |
| Sponsor | Hormozgan University of Medical Sciences |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors (PHASE1)
- Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) (PHASE1)
- Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) (PHASE2)
- Early Screening and Treatment of Heart Complication in Sickle Cell Disease (PHASE2)
- Synergistic Minimally Invasive Surgery and Deferoxamine in ICH (PHASE2, PHASE3)
- The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL (PHASE3)
- Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography) (EARLY_PHASE1)
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desferal CI brief — competitive landscape report
- Desferal updates RSS · CI watch RSS
- Hormozgan University of Medical Sciences portfolio CI